18F-FDG PET/CT对非小细胞肺癌EGFR基因突变诊断价值的Meta分析

 目的 采用Meta分析系统评价¹⁸F-FDG PET/CT对非小细胞肺癌EGFR基因突变的诊断价值。方法 计算机检索PubMed、EMbase、The Cochrane Library、中国期刊全文数据库、万方数据库、中文科技期刊数据库,查找有关¹⁸F-FDG PET/CT对非小细胞肺癌EGFR基因突变的诊断性试验。由 2 位评价员按照纳入与排除标准独立筛选文献、提取资料和评价纳入研究的方法学质量后,采用Meta DiSc1.4软件进行Meta分析。结果 最终纳入16篇文献,非小细胞肺癌3308例。病理确诊为肺腺癌2914例(88.09%),其他病理类型394例(11.91%)。Meta分析结果示,SEN合并=0.57[95%CI(0.55,0.60)],SPE合并=0.65[95%CI(0.62,0.67)],+LR合并=1.82[95%CI(1.49,2.23)],-LR合并=0.67[95%CI(0.59,0.76)],DOR合并=2.93[95%CI(2.08,4.15)],AUC=0.6678。结论 ¹⁸F-FDG PET/CT的SUV_max对NSCLC患者的EGFR突变有一定的预测能力,其特异度优于敏感度,可以用于EGFR突变的诊断。

Diagnostic value of 18F-FDG PET/CT for EGFR gene mutation in non-small cell lung cancer:a Meta analysis

Objective To evaluate the diagnostic value of ¹⁸F-FDG PET/CT for EGFR gene mutation in non-small cell lung cancer with Meta analysis.Methods Databases that had been searched included PubMed, EMbase, the Cochrane Library, Chinese Journal Full-text Database, Wanfang Database, Chinese Science and Technology Database. Diagnostic tests related to EGFR gene mutation in non-small cell lung cancer and involving ¹⁸F-FDG PET/CT were investigated and analyzed. Meta-analysis was performed using Meta DiSc 1.4 software after two reviewers independently screened the literature for inclusion and exclusion criteria, extracted the data and evaluated the methodological quality of the included studies.Results 16 articles and 3308 cases of non-small cell lung cancer patients were included. Meta-analysis results showed that the incorporated SEN averaged 0.57[95% CI (0.55,0.60)], incorporated SPE 0.65[95% CI (0.62,0.67) CI (1.49,2.23)], incorporated LR 0.67[95% CI (0.59,0.76)], and incorporated DOR 2.93[95% CI (2.08,4.15)], while AUC was 0.6678.Conclusions SUVmax of ¹⁸F-FDG PET/CT is of predictive value for the mutation of EGFR in NSCLC patients with better specificity than sensitivity, which can be used to predict the mutation of EGFR in NSCLC patients.